# Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/letrozole-ribociclib

> The FDA approved Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate), sponsored by NOVARTIS AG (NVS), on May 4, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) |
| Codes |  |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### May 4, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209935 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20170504, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22

### July 6, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209935 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20200706, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22

### December 10, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209935 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20211210, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22

### October 3, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209935 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20221003, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22

### September 17, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209935 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20240917, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22

### July 1, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209935 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20260701, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/letrozole-ribociclib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/letrozole-ribociclib

```bibtex
@misc{secapidev_pdufa_letrozole_ribociclib_20261116,
  title        = {Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/letrozole-ribociclib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_letrozole_ribociclib_20261116","title":"Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/letrozole-ribociclib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
